Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates

Journal of Infectious Diseases

Volumn 186, Issue 5, 2002, Pages 661-667

  Hussain, Farid M ^a   Boyle Vavra, Susan ^a   Shete, Priya B ^a   Daum, Robert S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; GLYCOPEPTIDE; METICILLIN; TRITON X 100; VANCOMYCIN;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CULTURE MEDIUM; HUMAN; INCUBATION TIME; ISOLATION PROCEDURE; LABORATORY DIAGNOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CULTURE MEDIA; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0036721545     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342708     Document Type: Article

References (28)

1. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
2. Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997
3. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
4. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus
5. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999
6. Vancomycin-resistant Staphylococcus aureus
7. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
8. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin
9. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
10. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin
11. Heterogeneous vancomycin-resistance in methicillin-resistant Staphylococcus aureus strains in a large Italian hospital
12. Emergence of heterogeneous intermediate vancomycin-resistance in Staphylococcus aureus isolates in the Dusseldorf area
13. Emergence of vancomycin resistance in Staphylococcus aureus
14. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
15. Development of lysostaphin and vancomycin resistance in pre-GISA vancomycin-tolerant, methicillin-resistant Staphylococcus aureus isolate
16. A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy
17. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
18. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage
19. M7A4 performance standards for antimicrobial susceptibility testing: Approved standard
20. Glycopeptide tolerance in Staphylococcus aureus
21. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
22. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus
23. Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected US Hospitals
24. Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds
25. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates
26. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50
27. In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus
28. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin